Nifty
:
23349.90
Sensex
:
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)
Nifty
Sensex
:
:
23349.90
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1303.55
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1255.00
  •  1311.80
  •  1255.00
  •  1254.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2708670
  •  35059.01
  •  1592.00
  •  958.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 70,799.72
  • 20.21
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 72,050.88
  • 0.37%
  • 2.34

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.82%
  • 0.44%
  • 5.33%
  • FII
  • DII
  • Others
  • 16.59%
  • 23.19%
  • 2.63%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.12
  • 4.66
  • 7.33

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.59
  • 3.73
  • 5.91

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.25
  • 2.10
  • 6.21

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.79
  • 14.26
  • 18.14

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.56
  • 2.03
  • 1.77

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.97
  • 9.20
  • 9.26

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
7,796.07
7,219.42
7.99%
7,567.02
6,850.52
10.46%
7,580.15
6,472.96
17.10%
7,351.78
6,407.13
14.74%
Expenses
6,229.93
5,845.98
6.57%
5,947.45
5,699.15
4.36%
5,907.34
5,470.78
7.98%
5,750.47
5,452.72
5.46%
EBITDA
1,566.14
1,373.44
14.03%
1,619.57
1,151.37
40.66%
1,672.81
1,002.18
66.92%
1,601.31
954.41
67.78%
EBIDTM
20.09%
19.02%
21.40%
16.81%
22.07%
15.48%
21.78%
14.90%
Other Income
136.00
186.98
-27.26%
220.93
116.33
89.92%
135.62
134.91
0.53%
162.52
92.65
75.41%
Interest
112.70
68.18
65.30%
111.04
56.55
96.36%
89.43
55.60
60.85%
75.55
44.96
68.04%
Depreciation
382.28
417.50
-8.44%
404.18
326.56
23.77%
354.33
345.57
2.53%
423.27
321.40
31.70%
PBT
1,207.16
1,074.74
12.32%
1,325.28
814.84
62.64%
1,242.56
735.92
68.84%
1,265.01
680.70
85.84%
Tax
390.51
323.70
20.64%
405.67
242.32
67.41%
322.55
224.15
43.90%
322.45
189.10
70.52%
PAT
816.65
751.04
8.74%
919.61
572.52
60.62%
920.01
511.77
79.77%
942.56
491.60
91.73%
PATM
10.48%
10.40%
12.15%
8.36%
12.14%
7.91%
12.82%
7.67%
EPS
14.07
12.92
8.90%
15.69
9.74
61.09%
15.51
8.64
79.51%
15.98
8.38
90.69%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
30,295.02
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
Net Sales Growth
12.41%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
 
Cost Of Goods Sold
12,494.40
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
Gross Profit
17,800.62
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
GP Margin
58.76%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
Total Expenditure
23,835.19
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
Power & Fuel Cost
-
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
% Of Sales
-
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
Employee Cost
-
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
% Of Sales
-
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
Manufacturing Exp.
-
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
% Of Sales
-
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
General & Admin Exp.
-
1,534.59
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
% Of Sales
-
5.29%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
Selling & Distn. Exp.
-
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
% Of Sales
-
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
Miscellaneous Exp.
-
650.10
698.93
419.58
576.06
529.75
413.24
298.75
203.97
212.65
878.98
% Of Sales
-
2.24%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
EBITDA
6,459.83
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
EBITDA Margin
21.32%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
Other Income
655.07
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
Interest
388.72
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
Depreciation
1,564.06
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
PBT
5,040.01
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
Tax
1,441.18
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
Tax Rate
28.59%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
PAT
3,598.83
3,172.97
1,927.50
2,648.15
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
PAT before Minority Interest
3,597.98
3,168.97
1,927.65
2,647.11
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
Minority Interest
-0.85
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
PAT Margin
11.88%
10.94%
7.75%
11.29%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
PAT Growth
54.66%
64.62%
-27.21%
-50.87%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
 
EPS
61.96
54.63
33.19
45.59
92.81
49.25
40.67
41.67
39.54
34.84
27.13

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
Total Reserves
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
Non-Current Liabilities
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
Secured Loans
2,134.90
618.96
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
Long Term Provisions
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
Current Liabilities
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
Trade Payables
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
Other Current Liabilities
3,070.63
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
Short Term Borrowings
4,168.54
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
Short Term Provisions
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
Total Liabilities
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
Net Block
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
Gross Block
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
Accumulated Depreciation
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
Non Current Assets
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
Capital Work in Progress
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
Non Current Investment
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
Long Term Loans & Adv.
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
Other Non Current Assets
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
Current Assets
23,771.92
21,459.91
18,043.59
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
Current Investments
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
Inventories
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
Sundry Debtors
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
Cash & Bank
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
Other Current Assets
2,818.07
554.71
393.95
601.29
1,555.31
2,715.72
1,977.28
1,596.81
831.25
659.57
Short Term Loans & Adv.
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
Net Current Assets
11,572.79
9,966.13
9,887.61
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
Total Assets
43,425.16
39,126.74
33,554.03
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
PBT
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
Adjustment
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
Changes in Working Capital
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
Cash after chg. in Working capital
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
Net Fixed Assets
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
Net Investments
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
Others
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
Cash from Financing Activity
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
Net Cash Inflow / Outflow
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
Opening Cash & Equivalents
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
Closing Cash & Equivalent
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
ROA
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
ROE
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
ROCE
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
Fixed Asset Turnover
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
Receivable days
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
Inventory Days
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
Payable days
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
Cash Conversion Cycle
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
Total Debt/Equity
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
Interest Cover
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69
14.56

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Aurobindo Pharma’s arm gets GMP certificate of compliance for Hyderabad facility
    13th Nov 2024, 10:59 AM

    The GMP inspection was conducted by EMA representatives from April 8 to April 12, 2024

    Read More
  • Aurobindo Pharma’s Q2FY25 consolidated net profit rises by 9%
    11th Nov 2024, 11:26 AM

    Consolidated total income of the company increased by 7.10% at Rs 7,932.07 crore for Q2FY25

    Read More
  • Aurobindo Pharma - Quarterly Results
    9th Nov 2024, 19:13 PM

    Read More
  • Aurobindo Pharma completes acquisition of balance 49% stake of GLS Pharma
    28th Oct 2024, 10:51 AM

    The aforementioned acquisition has been completed on October 25, 2024

    Read More
  • Aurobindo Pharma’s arm to sell 50% shares in Novagen
    5th Oct 2024, 12:01 PM

    After the disposal of 50% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen

    Read More
  • Aurobindo Pharma gets USFDA’s final approval for Cephalexin Tablets
    1st Oct 2024, 16:25 PM

    The product is expected to be launched in Q3FY25

    Read More
  • Aurobindo Pharma inks pact to acquire balance 49% stake in GLS Pharma
    18th Sep 2024, 17:15 PM

    The completion of the acquisition is estimated before December 31, 2024

    Read More
  • Aurobindo Pharma’s arm gets EIR for Andhra Pradesh facility
    18th Sep 2024, 11:58 AM

    The USFDA had conducted an inspection from March 28, 2024 to April 05, 2024 at this facility

    Read More
  • Aurobindo Pharma’s unit recalling products in US market over manufacturing issues
    27th Aug 2024, 12:24 PM

    Some bottles are missing the manufacturer's label that includes the drug facts information

    Read More
  • USFDA pulls up Aurobindo Pharma's arm for manufacturing lapses at Telangana-based plant
    26th Aug 2024, 11:43 AM

    A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

    Read More
  • Aurobindo Pharma to commence production in China facility
    19th Aug 2024, 14:26 PM

    The Hyderabad-based drug major plans to start a small volume roll out in the November-December period

    Read More
  • Aurobindo Pharma’s arm gets warning letter from USFDA for Unit-III
    16th Aug 2024, 11:41 AM

    There is no impact on the existing supplies to the US markets

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.